<VariationArchive VariationID="1440254" VariationName="NM_000353.3(TAT):c.966del (p.Ile322fs)" VariationType="Deletion" Accession="VCV001440254" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-28" DateCreated="2022-03-28" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1368704" VariationID="1440254">
      <GeneList>
        <Gene Symbol="TAT-AS1" FullName="TAT antisense RNA 1" GeneID="100132529" HGNC_ID="HGNC:51369" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16q22.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="71565016" stop="71572438" display_start="71565016" display_stop="71572438" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="TAT" FullName="tyrosine aminotransferase" GeneID="6898" HGNC_ID="HGNC:11573" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16q22.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="71565660" stop="71577092" display_start="71565660" display_stop="71577092" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="71600753" stop="71610997" display_start="71600753" display_stop="71610997" Strand="-" />
          </Location>
          <OMIM>613018</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000353.3(TAT):c.966del (p.Ile322fs)</Name>
      <CanonicalSPDI>NC_000016.10:71570343:AA:A</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16q22.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="71570344" stop="71570344" display_start="71570344" display_stop="71570344" variantLength="1" positionVCF="71570343" referenceAlleleVCF="CA" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="71604247" stop="71604247" display_start="71604247" display_stop="71604247" variantLength="1" positionVCF="71604246" referenceAlleleVCF="CA" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>I322fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.71570345del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.71570345del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.71604248del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.71604248del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008235.1" sequenceAccession="NG_008235" sequenceVersion="1" change="g.11752del">
            <Expression>NG_008235.1:g.11752del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000353.3" sequenceAccession="NM_000353" sequenceVersion="3" change="c.966del" MANESelect="true">
            <Expression>NM_000353.3:c.966del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000344.1" sequenceAccession="NP_000344" sequenceVersion="1" change="p.Ile322fs">
            <Expression>NP_000344.1:p.Ile322fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2145230737" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000353.3(TAT):c.966del (p.Ile322fs) AND Tyrosinemia type II" Accession="RCV001950359" Version="3">
        <ClassifiedConditionList TraitSetID="110">
          <ClassifiedCondition DB="MedGen" ID="C0268487">Tyrosinemia type II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-02-18" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-02-18" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">9544843</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="110" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5080" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Tyrosinemia type II</ElementValue>
                <XRef ID="MONDO:0010160" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Richner Hanhart syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">TAT deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tyrosine transaminase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Keratosis palmoplantaris with corneal dystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Oregon type tyrosinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tyrosinosis oculocutaneous type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tyrosine aminotransferase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Oculocutaneous tyrosinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tyrosinemia type 2</ElementValue>
                <XRef ID="Tyrosinemia+type+2/7282" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TYRSN2</ElementValue>
                <XRef Type="MIM" ID="276600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3105" />
                <XRef ID="3105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tyrosine.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Tyrosine, Tyrosinemia, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tryosine-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Tyrosine Elevated, Succinylacetone Normal, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tyrosine-Normal-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Tyrosine Normal/Elevated, Succinylacetone Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="28378" DB="Orphanet" />
              <XRef ID="C0268487" DB="MedGen" />
              <XRef ID="MONDO:0010160" DB="MONDO" />
              <XRef Type="MIM" ID="276600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4243126" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="13158855|MedGen:C0268487" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002226500" DateUpdated="2024-02-28" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-02-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9544843</ID>
          </Citation>
          <Comment>This variant has not been reported in the literature in individuals with TAT-related conditions. For these reasons, this variant has been classified as Pathogenic. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Ile322Metfs*6) in the TAT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TAT are known to be pathogenic (PMID: 9544843).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TAT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.71604247del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268487" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4243126" TraitType="Disease" MappingType="XRef" MappingValue="C0268487" MappingRef="MedGen">
        <MedGen CUI="C0268487" Name="Tyrosinemia type II" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

